Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206
Top Cited Papers
- 10 December 2005
- journal article
- melanoma
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (35) , 8968-8977
- https://doi.org/10.1200/jco.2005.01.109
Abstract
Purpose Cytotoxic T lymphocyte–associated antigen 4 (CTLA4) blockade with CP-675,206, a fully human anti-CTLA4 monoclonal antibody, may break peripheral immunologic tolerance leading to effective i...Keywords
This publication has 29 references indexed in Scilit:
- Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenaseInternational Immunology, 2004
- Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodesJournal of Clinical Investigation, 2004
- Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune diseaseProceedings of the National Academy of Sciences, 2004
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- CTLA-4–Ig regulates tryptophan catabolism in vivoNature Immunology, 2002
- Expression of CTLA‐4 by Human MonocytesScandinavian Journal of Immunology, 2002
- IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature, 2001
- CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor ImmunotherapyAnnual Review of Immunology, 2001
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 1995